When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Chemotherapy given in conjunction with regional hyperthermia produces good response rates in children and adolescents with refractory or recurrent germ-cell tumors, German researchers…
NEW YORK (Reuters Health) – When the cell adhesion molecule L1CAM is expressed in early-stage endometrial tumors, there is a 50% chance of recurrence, a multicenter study has…
NEW YORK (Reuters Health) – Men with azoospermia have a risk of developing cancer 2.9 times higher than the general population, according to data from a Texas andrology…
By Andrew M. Seaman NEW YORK (Reuters Health) – Low-dose aspirin, even if not taken daily, may reduce a woman’s risk of colon cancer over the long term,…
NEW YORK (Reuters Health) – Physicians caring for women who are at increased risk for breast cancer should discuss with them the risks and benefits of specific chemoprevention…
By David Douglas NEW YORK (Reuters Health) – Mammalian target of rapamycin (mTOR) inhibitor treatment has been linked with acute tubular necrosis (ATN) in four case reports from…
Salim Ismail, Founding Executive Director, Singularity University, gives you the top 5 medical breakthroughs by 2020 that will revolutionize medicine in the healthcare sector. Read more about Salim…
Jack Andraka, recipient of the 2012 Gordon E. Moore Award, explains the process of developing a cheap, fast, and 100% accurate diagnostic test for pancreatic cancer. Drawing from…
NEW YORK (Reuters Health) – A small study indicates that most patients with cutaneous B-cell lymphoma who respond well to rituximab relapse after about two years. On the…
NEW YORK (Reuters Health) – Contrary to a historically pessimistic outlook, high-risk prostate cancer can be controlled with moderate high-dose radiation treatment and prolonged androgen-deprivation therapy (ADT). That…
